Bias in clinical AI is any factor that makes an algorithm produce different or inequitable results for different patient groups. It rarely comes from one bad line of code. It enters through who is in the training data, what the model is asked to predict, how it is deployed, and whether anyone watches it afterward. The good news for healthtech teams is that most of these sources can be found and managed, if someone with clinical judgment is in the room when the decisions are made.
This guide explains what bias means in a clinical setting, where it enters, which documented cases matter, and what US guidance expects from developers and health systems.
TL;DR
- Bias in clinical AI means differential or inequitable outputs and outcomes across patient groups, and it can enter at every stage of the AI life cycle, from concept to post-deployment monitoring.
- Documented cases include a risk algorithm that used healthcare cost as a proxy for need, and imaging and pathology models that performed unevenly across groups.
- US guidance from the FDA and ONC points to representative data, transparency about known limitations, and ongoing surveillance.
- Mitigation works best as a cross-functional practice: data, engineering, clinical leadership, and governance together.
- A fractional Chief Medical Officer can supply the clinical oversight that early-stage healthtech teams often lack.
Table of Contents
- What bias in clinical AI actually means
- Where bias enters the AI life cycle
- Documented examples worth knowing
- How biased AI affects patients and organizations
- What US guidance expects
- How to test, reduce, and monitor bias
- Governance: who owns bias in your company
- Our perspective
- Getting clinical oversight without a full-time hire
- Practical checklist before you ship
- FAQ
- Sources
What bias in clinical AI actually means
A 2024 review of bias in medical AI defines it as any instance, factor, or prejudice that drives an algorithm to produce differential or inequitable outputs and outcomes. The same paper roots the problem in long-standing inequalities in healthcare, which models can inherit from the data they learn from.
That is different from ordinary model error. Every model is wrong some of the time. Bias is the pattern in who it is wrong for. A sepsis model with 90% overall accuracy can still miss disproportionately more cases in one population. The average hides the gap.
It also helps to separate two terms that get blurred. Researchers Paulus and Kent note that fairness concerns apply when models support decisions such as resource allocation, while bias refers to data or model problems that lead to differentially harmful or beneficial predictions regardless of the decision context. In practice, you measure bias in the model and you judge fairness in how its outputs are used.
Where bias enters the AI life cycle
Teams often look for bias only at the training stage. The evidence says that is too late and too narrow. A 2025 npj Digital Medicine review finds that bias can arise at every stage: conception, data collection, pre-processing, algorithm development, clinical deployment, and post-deployment surveillance.
| Stage | How bias can enter | Question to ask |
|---|---|---|
| Conception | The problem is framed around one population's needs or workflow | Who was consulted on the use case, and who was not? |
| Data collection | Some groups are underrepresented, or data reflects unequal access to care | Does the dataset resemble the patients who will actually be scored? |
| Pre-processing | Labels, missing values, and proxies encode past practice | What does the label really measure? |
| Model development | Optimization targets overall accuracy and ignores subgroup performance | Are results reported by subgroup? |
| Deployment | The tool is used on different patients or in different workflows than tested | Does it perform the same at our site? |
| Surveillance | Populations, practice patterns, and data drift over time | Who owns monitoring, and what triggers action? |
One more point from a primer on bias in AI: model selection, training, and testing are often opaque, so the buyers of clinical AI may not know how modeling decisions shaped performance gaps. That matters for any startup selling into health systems. Your customer's clinical informatics team will ask.
Bias that has nothing to do with the data alone
Human factors count too. The same primer notes that clinician trust and acceptance affect how AI is used in the real world, and that differences in patients' health literacy and cultural acceptance can lead to missed opportunities to improve outcomes. A model can be statistically sound and still produce uneven results if one group of clinicians overrides it more often, or one group of patients is less likely to receive the follow-up it triggers.
Documented examples worth knowing
Founders sometimes treat algorithmic bias as a theoretical risk. The record says otherwise.
Cost as a proxy for need. One widely discussed risk algorithm used healthcare spending as its outcome. Because less money was spent on Black patients than on White patients with similar morbidity, the tool preferentially recommended White patients for extra care resources, as described in the bias primer. The model did what it was told. The label was the problem.
Imaging and diagnosis. A review of algorithm fairness in medicine reports convolutional neural networks that underdiagnosed and misdiagnosed Hispanic patients and patients on Medicaid at disproportionate rates compared with White patients.
Spurious signals in pathology. The same review describes pathology models that inferred patient ethnicity from hospital-specific H&E staining. The model learned a site artifact that correlates with a demographic group, which can reinforce inequity when it influences predictions.
Three different mechanisms, one lesson: bias is usually found by someone asking a clinical question about the data, not by a metric alone.
How biased AI affects patients and organizations
The 2024 review warns that left unaddressed, biased medical AI can lead to substandard clinical decisions, incorrect treatment recommendations, and inequitable allocation of limited resources, and can perpetuate or worsen existing disparities.
For a healthtech company, the consequences stack up beyond patient harm:
- Sales friction. Health system buyers increasingly ask for subgroup performance and governance documentation during procurement.
- Regulatory exposure. FDA and ONC expectations, covered below, are moving toward documented transparency.
- Investor diligence. Investors backing clinical AI want to know the team can detect and manage model risk, since a single public failure can stall adoption.
- Clinician trust. Physicians who see a tool misfire on their patients stop using it, and that is hard to reverse.
What US guidance expects
There is no single US "bias law" for clinical AI. Expectations come from several places, and which apply depends on whether your product is a regulated device, certified health IT, or an internal decision-support tool.
FDA. The agency's Good Machine Learning Practice principles recommend that clinical study participants and datasets represent the intended patient population across characteristics such as age, sex, race, and ethnicity, so bias is managed and performance generalizes. Its related transparency principles encourage developers to give users clear information, including known biases, failure modes, confidence intervals, and limitations.
ONC. The HTI-1 Final Rule sets transparency requirements for AI and other predictive algorithms that are part of certified health IT, so clinical users can assess them for fairness, appropriateness, validity, effectiveness, and safety. If you sell certified health IT, our HTI-1 implementation checklist walks through the practical steps.
National Academy of Medicine. Its guiding principles on algorithm bias suggest promoting equity in all algorithm phases, ensuring transparency, engaging patients and communities, explicitly identifying fairness trade-offs, and establishing accountability for outcomes. These are not binding rules, but they describe what a mature governance program looks like.
For teams building the legal and risk side of this work, a structured AI model risk management roadmap can help organize responsibilities across the model life cycle.
How to test, reduce, and monitor bias
Technical fixes matter, but they sit inside a process. Here is a sequence that works for most healthtech teams.
1. Define the clinical question and the label first
Before any modeling, write down what the model predicts, for whom, and what decision it informs. Then interrogate the label. If it is a proxy (cost, utilization, prior diagnosis), ask whose care patterns it reflects. The cost-as-need case shows how a sensible-looking proxy can embed inequity.
2. Check that your data represents the intended population
Compare the training and validation data with the patients who will actually be scored. Look at age, sex, race, ethnicity, payer, geography, and care setting. Where you are working with sensitive records, your de-identification approach also shapes what demographic detail survives, so see our guide to audit-ready HIPAA de-identification. Data quality and lineage belong here too, and a data governance roadmap gives you a 90 to 180 day structure.
3. Report performance by subgroup
Overall accuracy is not enough. Report sensitivity, specificity, calibration, and error rates by relevant subgroup, with confidence intervals. The npj Digital Medicine review notes that what counts as a "meaningful" bias is not uniform and must be assessed case by case, with nominal performance thresholds set so surveillance can run automatically and iteratively. Decide your thresholds with clinicians before you see the results, not after.
4. Apply technical mitigation where it fits
The same review groups mitigation into three types:
- Pre-processing: for example, reweighting samples.
- In-processing: for example, adding fairness constraints to the objective function.
- Post-processing: for example, recalibrating thresholds for different subgroups.
Each has trade-offs, and the National Academy of Medicine guidance says to identify those trade-offs explicitly. A clinician should weigh in on which error is worse for a given use: a missed case or a false alarm.
5. Design with the users, not just for them
Human-centered design helps identify users' context of use and information needs and supports usability evaluation of AI systems, according to a 2023 study on human-centered design and bias. Test the tasks where a wrong output does the most damage. Our guide to usability testing for healthcare software starts with exactly those critical tasks.
6. Monitor after launch
Performance drifts as populations, coding practices, and workflows change. Assign an owner, set triggers for review, and keep a log of what you changed and why. Health systems treat that log as evidence of accountability. Strong health data analytics practice makes this monitoring far easier to sustain.
Governance: who owns bias in your company
The National Academy of Medicine principles end on accountability, and that is where early-stage teams often have a gap. Engineers own the model. Compliance owns the paperwork. Nobody owns the clinical question: is this output safe and appropriate for this patient?
A workable structure is simple:
- A named executive accountable for clinical safety of AI features.
- A review step before release that includes subgroup results and known limitations.
- A customer-facing summary of intended use, data sources, and known limitations, consistent with FDA transparency principles.
- A post-deployment review on a fixed schedule.
Organizations in other settings face the same governance question. Reading about AI in veterans' health care shows how data-driven programs depend on trust, transparency, and accountable oversight to reach the people they are meant to serve.
For a deeper look at causes and fixes from our own team, see our post on AI bias in healthcare models.
Our perspective
Most of the bias problems I see in healthtech are not exotic. They are ordinary decisions made without a clinician in the room: a label chosen because it was available, a validation set drawn from one health system, a threshold set for overall accuracy.
We approach bias as a clinical leadership question as much as a technical one. Someone has to ask what the model is really measuring, which patients it was never tested on, and what happens at the bedside when it is wrong. That person needs to understand both patient care and how a startup actually ships product.
That is the gap a fractional Chief Medical Officer is built to close. Early-stage teams rarely need a full-time CMO, but they do need medical judgment at the moments that matter: use case definition, validation design, customer conversations, and investor diligence. We provide that hands-on, grounded in real patient care and startup growth experience.
If something about your model's performance feels misaligned, I would welcome a conversation.
Paul Bergeron MD, MBA
Getting clinical oversight without a full-time hire
The StartUp MD is a healthcare advisory firm for healthcare SaaS and digital health companies. We offer Fractional Chief Medical Officer engagements and project-based advisory work, including clinical strategy, product evaluation, regulatory guidance, and investor support. For teams working through bias questions, that can mean reviewing your validation approach, pressure-testing how a model fits clinical workflows, and preparing the clinical story buyers and investors will ask about.
See how we work on our services page, or learn more about The StartUp MD.
Practical checklist before you ship
- The prediction target and label are documented, and any proxy has been challenged by a clinician.
- Training and validation data are compared against the intended patient population.
- Performance is reported by subgroup, with thresholds agreed in advance.
- Known limitations and failure modes are written down in plain language for users.
- A named owner and a schedule exist for post-deployment monitoring.
- Clinicians and end users tested the highest-risk tasks.
FAQ
Is bias in clinical AI the same as a model being inaccurate?
No. Inaccuracy is how often a model is wrong. Bias is whether its errors or benefits fall unevenly across patient groups. A model can look accurate overall while performing worse for a subgroup, which is why subgroup reporting matters.
Can bias in clinical AI be eliminated completely?
It is better to think in terms of identifying, reducing, and monitoring it. Bias can enter at every life cycle stage, and fairness choices involve trade-offs that should be made explicitly. Teams that document those choices and keep monitoring are in the strongest position.
Does the FDA require bias testing for AI medical devices?
FDA's Good Machine Learning Practice principles recommend representative datasets and study participants and encourage transparency about known biases and limitations. Whether and how these apply to your product depends on its regulatory pathway, so confirm with your regulatory counsel or the FDA directly.
What does HTI-1 mean for AI bias?
HTI-1 sets transparency requirements for AI and predictive algorithms that are part of certified health IT, so clinical users can evaluate them for fairness, validity, and safety. If you sell certified health IT, plan the documentation early.
Who should own bias review at a startup?
Someone with clinical authority and accountability for patient safety. Many early-stage companies do not have that person in-house, which is where a fractional CMO can help.
Sources
- Bias in medical AI: Implications for clinical decision-making
- Predictably unequal: understanding and addressing concerns that algorithmic clinical prediction may increase health disparities
- Bias recognition and mitigation strategies in artificial intelligence healthcare applications
- Bias in Artificial Intelligence: Basic Primer
- Algorithm fairness in artificial intelligence for medicine and healthcare
- Guiding Principles to Address the Impact of Algorithm Bias on Racial and Ethnic Disparities in Health and Health Care
- Human-Centered Design to Address Biases in Artificial Intelligence
- HTI-1 Final Rule, ONC
- Good Machine Learning Practice for Medical Device Development, FDA
- Transparency for Machine Learning-Enabled Medical Devices, FDA